In a new study, a comparative analysis of the efficacy of umeclidinium and vilanterol (UMEC-VI, trade name Anoro Ellipta, GlaxoSmithKline) bronchodilator fixed-dose showed that it was as effective as other available dual-bronchodilator combinations for treating COPD.

The authors conducted a meta-analysis to determine the efficacy of UMEC/VI (dose administration 55/22 ?g) with the available dual-combination bronchodilators in patients with moderate-to-very-severe COPD who were capable of receiving bronchodilator therapy.

The researchers performed a systematic review of literature of COPD patients’ clinical trials with at least 10 weeks duration, which evaluated combined bronchodilators efficacy in single or separate inhalers, according to Lung Disease News. The different bronchodilator setup was evaluated upon changes from baseline in forced expiratory volume in 1 second (FEV1), transitional dyspnea index (TDI) focal scores, St George’s Respiratory Questionnaire (SGRQ) total scores, and the need for rescue medication determined at 12 and 24 weeks.

In total, 77 articles that reported 26 clinical trials were analyzed. The research team observed that UMEC/VI efficiency is similar to all other dual fixed or open LABA/LAMA combination bronchodilators, including QVA149, TIO + FOR, TIO + SAL, and IND + TIO.

The Lung Disease News report notes that researchers highlight that this is the first study comparing the efficacy of several available fixed-dose bronchodilators in COPD patients as well as report the comparable efficacy of UMEC/VI to other available dual-bronchodilator combinations.

Source: Lung Disease News